1
Orphan Designations
0 approved, 1 designated
0
FDA Approvals
3
Active Trials
200 recruiting
4
Rare Diseases
across 8 areas
0
News (30d)
Quiet
New York University is a company with 1 orphan drug designation across 4 rare diseases. Active clinical trials in 3 indications. gene therapy candidates in 1 disease. 21 active policy bills affect their portfolio.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| Alzheimer disease | - | Des.TrialAppr. |
| Angelman syndrome | insulin like growth factor 2 receptor ligand | Des.TrialAppr. |
| cervical cancer | - | Des.TrialAppr. |
| sickle cell disease | - | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
26
overlap in 2+ diseases
1/4
candidate diseases
0
avg importance: 0
21
affecting portfolio
0% of portfolio targets high unmet need diseases
26
overlap in 2+ diseases
1/4
candidate diseases
0
avg importance: 0
21
affecting portfolio